Bath Ankylosing Spondylitis Disease Activity Index (BASDAI)
Bath Ankylosing Spondylitis Disease Activity Index · Also known as: BASDAI, BAS-DAI
The BASDAI is a patient-reported outcome measure of disease activity in ankylosing spondylitis (AS), a chronic inflammatory arthropathy affecting the spine and axial skeleton. Introduced by Garrett et al. in 1994, BASDAI uses six simple patient self-report items focused on the cardinal symptoms of AS: fatigue, spinal pain, peripheral joint involvement, and morning stiffness. As a PRO measure, BASDAI is practical for routine monitoring, responsive to treatment, and strongly associated with clinical outcomes and spinal damage progression, making it a cornerstone outcome in AS management and clinical trials.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
BASDAI is the primary outcome measure for assessing disease activity in patients with ankylosing spondylitis or other axial spondyloarthropathies (non-radiographic axial spondyloarthropathy [nr-axSpA]). Use at baseline to establish disease severity, then at regular intervals (monthly or every 6–12 weeks depending on treatment plan) to monitor therapy response. BASDAI is appropriate for both early disease and established spinal fusion. It is particularly useful for: (1) identifying patients with high disease activity (BASDAI ≥4) warranting DMARD or biologic therapy initiation; (2) monitoring response to NSAIDs, conventional DMARDs, or TNF-inhibitors; (3) patients with predominantly axial/spinal disease where peripheral joint assessment is limited; (4) telemedicine and remote monitoring; (5) pragmatic, real-world AS research. BASDAI is validated for adults; not validated for juvenile-onset AS or non-spondyloarthropathy conditions.
Strengths & limitations
- Patient-administered; no clinician training, equipment, or examination required—practical for primary care and telemedicine.
- Focused on cardinal AS symptoms (pain, stiffness, fatigue); responsive to the main features of AS disease.
- Strong responsiveness to TNF-inhibitor therapy; BASDAI response was pivotal in demonstrating biologic efficacy in AS trials.
- Simple, quick completion (2–3 minutes); enables frequent monitoring and patient self-directed assessment.
- Well-validated; extensively used in AS registries and major clinical trials (ATTRACT, ASAS-CHARM, etc.); standardised interpretation.
- MCID (1.1) is well-established, enabling precise detection of clinically meaningful change; BASDAI 50 (50% reduction from baseline) is a trial standard.
- Associated with spinal radiographic progression and physical function; elevated BASDAI predicts long-term spine damage.
- Depends entirely on patient self-report; accuracy influenced by pain catastrophising, psychological distress, fibromyalgia, or non-inflammatory pain conditions.
- Does not include objective inflammatory markers (ESR, CRP); cannot assess systemic inflammation independently.
- Item 4 (morning stiffness duration) requires patient conversion of minutes to a 0–10 scale, which adds subjectivity; calculation error is common.
- Limited sensitivity to peripheral joint involvement; BASDAI is primarily spinal and not suitable for monitoring peripheral arthritis.
- Does not capture spinal damage progression (radiographic ankylosis), which progresses independently of BASDAI activity.
- ASDAS (incorporating CRP) is increasingly preferred over BASDAI for remission definition; BASDAI-only remission may miss high-grade inflammation.
- Ceiling effects in severe disease; BASDAI cannot differentiate among very high activity states.
Frequently asked
What does a BASDAI of 4.5 mean?
A BASDAI of 4.5 indicates active disease (≥4) with moderate-to-high disease burden. Most AS guidelines recommend initiating or escalating DMARD or biologic therapy if BASDAI remains ≥4 despite NSAIDs. This score warrants review of medication adherence and consideration of TNF-inhibitor therapy if not yet tried.
What is the difference between BASDAI and ASDAS?
BASDAI includes six patient-reported items only; ASDAS (Ankylosing Spondylitis Disease Activity Score) incorporates BASDAI plus CRP or ESR. ASDAS is more sensitive to systemic inflammation and is preferred for remission definition (ASDAS <1.3). BASDAI remains useful for frequent patient self-monitoring; ASDAS is preferred for formal trial endpoints and remission assessment.
What if I have high BASDAI but normal CRP?
Discordance between BASDAI and CRP occurs in ~30% of AS patients. This may reflect early disease with active inflammation not yet reflected in acute-phase reactants, primary pain amplification syndromes, comorbid fibromyalgia, or depression. Consider MRI for subclinical spinal inflammation, psychological assessment, and clarification of BASDAI drivers (pain vs. stiffness vs. fatigue). Both BASDAI and objective markers should be integrated into clinical decisions.
How do I convert morning stiffness duration (in minutes) to the 0–10 scale?
BASDAI Item 4 asks 'How long is your morning stiffness?' with duration in minutes. The standard conversion is: 0 = 0 minutes, 1 = 10 minutes, 2 = 20 minutes, ..., 10 = 120+ minutes. Example: 45 minutes ≈ 4.5 on the 0–10 scale. Some questionnaires provide this scale pre-printed; if not, ask patients to provide duration in minutes and convert mathematically (minutes/12 ≈ VAS score, capped at 10).
Is BASDAI <4 the same as remission?
No. BASDAI <4 indicates acceptable disease activity and low progression risk, but does not define remission. ASAS remission criteria for AS are more stringent: ASDAS <1.3 or Boolean criteria (BASDAI ≤4 AND ESR ≤10 AND SJC=0). BASDAI <4 is the action threshold for therapy; remission requires stricter assessment.
Can BASDAI be used for psoriatic or reactive arthritis?
BASDAI is validated for ankylosing spondylitis and non-radiographic axial spondyloarthropathy. For other spondyloarthropathies (psoriatic arthritis, reactive arthritis), use disease-specific measures. BASDAI is not recommended for non-spondyloarthropathy conditions (e.g., RA).
What is BASDAI 50?
BASDAI 50 refers to a ≥50% reduction in BASDAI score from baseline. This is a standard efficacy endpoint in AS trials, demonstrating clinically meaningful response to therapy. For example, if baseline BASDAI = 6, then BASDAI 50 = achieving BASDAI ≤3 (50% reduction). BASDAI 50 responses are typically achieved in 40–60% of patients on TNF-inhibitors.
How often should BASDAI be assessed?
Baseline BASDAI is essential to establish disease severity. During treatment titration, assess every 4–6 weeks until stable remission is achieved, then every 3–6 months for maintenance. Some guidelines recommend monthly self-assessment; formal clinical review can be less frequent. Frequency depends on disease activity and treatment plan.
Sources
- Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. The Journal of Rheumatology. 1994;21(12):2286-2291. link ↗
How to cite this page
ScholarGate. (2026, June 3). Bath Ankylosing Spondylitis Disease Activity Index. ScholarGate. https://scholargate.app/en/rheumatology/basdai
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- Bath Ankylosing Spondylitis Functional IndexRheumatology↔ compare
- Disease Activity Score 28Rheumatology↔ compare
- Routine Assessment of Patient Index Data 3Rheumatology↔ compare
- Systemic Lupus Erythematosus Disease Activity IndexRheumatology↔ compare